The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Gram positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.
本发明涉及一种卤代
水杨酰苯胺,选自 closantel、rafoxanide、oxyclozanide 和 niclosamide 及其衍
生物,包括盐类、
水合物、
酯类等,用于局部治疗或预防革兰氏阳性菌如葡萄球菌(尤其是
金黄色葡萄球菌)和链球菌(尤其是化脓性链球菌)引起的感染。与常用的局部抗生素相比,使用卤代
水杨酰苯胺处理的革兰氏阳性细菌出现耐药性突变体的频率非常低。